Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression

Genomic characterization of cancer has enabled identification of numerous molecular targets, which has led to significant advances in personalized medicine. However, with few exceptions, precision medicine approaches in the plasma cell malignancy multiple myeloma (MM) have had limited success, likel...

Descripción completa

Detalles Bibliográficos
Autores principales: Croucher, Danielle C., Devasia, Anup Joseph, Abelman, Dor D., Mahdipour-Shirayeh, Ali, Li, Zhihua, Erdmann, Natalie, Tiedemann, Rodger, Pugh, Trevor J., Trudel, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2023
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240837/
https://www.ncbi.nlm.nih.gov/pubmed/36639200
http://dx.doi.org/10.1101/mcs.a006249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240837/
https://www.ncbi.nlm.nih.gov/pubmed/36639200
http://dx.doi.org/10.1101/mcs.a006249

Ejemplares similares